Find Clinical Trial

Phase II Randomized Study of BAX2398 in Combination With 5-Fluorouracil and Calcium Levofolinate in Japanese Patients With Metastatic Pancreatic Cancer, Which Progressed or Recurred After Prior Gemcitabine-Based Therapy


← Back
Study Phase

Phase 2

Therapeutic Area

Cancers

Active substance/
Medical device

Liposomal Irinotecan, S095013

SponsorInstitut de Recherches Internationales Servier
Active Substance CodeS095013
Protocol Code331501
NCT CodeNCT02697058


Documents and links

Results are not yet available.




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2017 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
More information

Report a side-effect with a drug.
Accessibility